Milestone Pharmaceuticals prices $52.5 million public offering

Milestone Pharmaceuticals Inc. (MIST) has priced an underwritten public offering at $1.50 per share, expecting to raise approximately $52.5 million to fund the clinical development and commercial launch of its lead cardiovascular drug candidate, etripamil for PSVT, and for general corporate purposes. This capital raise is crucial as the biopharmaceutical company is currently burning cash, despite a healthy current ratio. The offering follows Milestone's recent New Drug Application submission for etripamil and comes as the FDA set a December 13, 2025, target action date for its CARDAMYST nasal spray, another PSVT treatment, after the company successfully addressed prior regulatory concerns, with analysts projecting significant peak sales for CARDAMYST.

Analysis

Milestone Pharmaceuticals is securing its operational runway with a significant public offering expected to raise approximately $52.5 million, priced at $1.50 per share. This capital injection is critical as the company is described as burning through cash, making the funds essential for the clinical development and potential commercial launch of its lead drug candidate, etripamil for PSVT. The financing occurs at a pivotal regulatory moment, following the submission of a New Drug Application for etripamil and the FDA's acceptance of its response to a prior Complete Response Letter for its CARDAMYST nasal spray. The establishment of a December 13, 2025, target action date for CARDAMYST is a major de-risking event, resolving previous concerns over impurities and manufacturing. Analyst outlook appears constructive, with H.C. Wainwright maintaining a buy rating and projecting potential peak sales for CARDAMYST could exceed $700 million, signaling substantial commercial upside. However, the offering represents significant dilution for current shareholders, given the company's $118 million market capitalization, a necessary trade-off to bridge the financial gap to potential commercialization.

Key Decisions for Investors

• Investors with a high-risk tolerance may consider the offering a de-risked entry point ahead of the key December 13, 2025 PDUFA date for CARDAMYST, which has a significant peak sales estimate.
• Current shareholders must factor in the substantial near-term dilution from the offering priced at $1.50 per share, a necessary step to fund operations and mitigate the cash burn risk ahead of potential revenue.
• It is prudent to monitor the successful closing of the financing, any updates on the commercial launch strategy for etripamil, and further regulatory communications, as these will be key performance indicators ahead of the 2025 catalyst.